Stocks
Vaxart Targets H1 2027 for Phase IIb COVID-19 Data, Backed by BARDA
Vaxart (VXRT) announced plans to release top-line data from its Phase IIb COVID-19 trial in the first half of 2027, supported by...
#clinical trials 7 articles
Stocks
Summit Therapeutics Sets November 14 FDA PDUFA Date for Ivonescimab
Summit Therapeutics has received a November 14 PDUFA date for its ivonescimab BLA. The company is also planning the HARMONi-3 PFS trial...
Stocks
Lilly’s Retatrutide Shows Broad Benefits in Obesity Trials
Eli Lilly's experimental obesity drug retatrutide delivered positive late-stage trial results, showing substantial weight loss and improvements in type 2 diabetes, knee...
Stocks
Incyte’s Monjuvi Lifts Lymphoma Survival 25% in Late-Stage Trial
Incyte's immunotherapy Monjuvi, developed with Xencor, demonstrated a 25% improvement in cancer-free survival in a late-stage trial for a common lymphoma type,...
Stocks
Longeveron Sets August 2026 ELPIS II Readout, Adopts Asset-Light Model
Longeveron (LGVN) targets an August 2026 readout for its ELPIS II study, simultaneously shifting to an asset-light partnering model under new leadership....
Stocks
Vaxart Sets Early 2027 Efficacy Readout, Q2 Sentinel Data Release Imminent
Vaxart (VXRT) anticipates a primary efficacy readout for its oral vaccine platform in early 2027, with a Q2 sentinel data release expected...
Stocks
AZN’s Imfinzi Combo Wins Late-Stage Liver Cancer Trial
AstraZeneca (AZN) announced a successful late-stage trial for its Imfinzi combination regimen in a subset of liver cancer patients, bolstering the company's...